Zura Bio (ZURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 May, 2026Board of directors and corporate governance
Someit Sidhu resigned from the board of directors effective May 21, 2026, with no disagreements regarding company operations, policies, or practices.
Voting matters and shareholder proposals
Definitive additional proxy materials were filed, indicating ongoing or upcoming shareholder voting matters.
Shareholder rights and capital structure
Class A Ordinary Shares are registered and traded on The Nasdaq Stock Market under the symbol ZURA.
The company is incorporated in the Cayman Islands and is classified as an emerging growth company.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zura Bio
- Q1 net loss increased to $24.2M, but cash reserves rose to $225.6M after a $144M equity raise.ZURA
Q1 20267 May 2026 - Tibulizumab targets dual immune pathways in Phase 2 trials for HS and SSc, with data expected 2026–2027.ZURACorporate presentation7 May 2026
- Proxy covers director elections, auditor ratification, equity plan changes, and governance updates.ZURAProxy filing30 Apr 2026
- First-in-class dual-pathway antibody in Phase 2 for HS and SSc, targeting major unmet needs.ZURACorporate presentation26 Apr 2026
- Phase 2 trials advanced, $144M raised, and cash runway secured through 2028.ZURAQ4 202519 Mar 2026
- Pivotal phase II data for tibulizumab in HS expected Q4, with SSc data in 2027.ZURALeerink Global Healthcare Conference 202613 Mar 2026
- First-in-class dual-pathway antibody in Phase 2 for HS and SSc, with data expected 2026–2027.ZURACorporate presentation10 Mar 2026
- Pivotal phase II data for tibulizumab in HS and SSc expected within 12-18 months.ZURAGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- First-in-class dual-pathway antibody in Phase 2 for HS and SSc, targeting major unmet needs.ZURACorporate presentation11 Feb 2026